Skip Navigation LinksHome > July 1, 2005 - Volume 39 - Issue 3 > Efficacy and Tolerability of a Nucleoside Reverse Transcript...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
Clinical Science

Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients

Allavena, Clotilde MD*; Ferré, Virginie PharmD, PhD†; Brunet-François, Cécile MD*; Delfraissy, Jean-François MD, PhD‡; Lafeuillade, Alain MD§; Valantin, Marc-Antoine MD∥; Bentata, Michelle MD¶; Michelet, Christian MD, PhD#; Poizot-Martin, Isabelle MD**; Dailly, Eric MD††; Launay, Odile MD¶; Raffi, François MD, PhD*; the Bitherapy Kaletra-Sustiva Study Group

Free Access
Article Outline
Collapse Box

Author Information

From the *Service des Maladies Infectieuses et Tropicales/IFR26, Hôtel-Dieu, Nantes, France; †Laboratoire de Virologie/IFR26, Hôtel-Dieu, Nantes, France; ‡Service de Médecine Interne, Hôpital Bicêtre, Paris, France; ¶Service de Médecine Interne Hôpital Avicenne, Bobigny, France; §Service de Maladies Infectieuses, Hôpital Chalucet, Toulon, France; ∥Service de Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Paris, France; #Service de Maladies Infectieuses, Hôpital Pontchaillou, Rennes, France; **Service d'Hématologie, Hôpital Sainte Marguerite, Marseille, France; and ††Laboratoire de Pharmacologie, Hôtel-Dieu, Nantes, France.

Received for publication November 29, 2004; accepted March 31, 2005.

Supported by the Association de Recherche sur le SIDA et les Infections des Immunodéprimés (ARSIID), Abbott Laboratories, and Bristol-Myers Squibb.

Reprints: François Raffi, Service des Maladies Infectieuses, Hôtel-Dieu, 1 Place Ricordeau, 44093 Nantes Cedex 1, France (e-mail:

Collapse Box


Background: Recommended antiretroviral regimens include a nucleoside reverse transcriptase inhibitor (NRTI) component. Class cross-resistance and mitochondrial toxicity are recognized as problems with this class of antiretrovirals.

Methods: In a pilot open-label study, 65 antiretroviral-naive and 21 experienced but nonnucleoside reverse transcriptase inhibitor-naive HIV-1-infected adults were given a combination of lopinavir/ritonavir (533.3/133.3 mg twice daily) and efavirenz (600 mg once daily) for 48 weeks.

Results: At baseline, the mean viral load was 4.84 log10 copies/mL and the mean CD4 count was 311 cells/mm3. At week 24, the proportions of patients with a viral load <400 copies/mL were 78% and 93% using an intent-to-treat and on-treatment analysis, respectively. At week 48, proportions were 73% and 97%, respectively. Treatment discontinuation occurred in 21 patients during the 48-week period, with 33% of those attributable to drug-related adverse effects. A viral load >400 copies/mL at week 24 or 48 was associated with nonadherence in 3 patients and virologic failure in 1 patient. After an increase during the first 8 weeks, fasting lipid levels remained stable up to 48 weeks.

Conclusion: The lopinavir/ritonavir-efavirenz combination is associated with a high rate of virologic response and should be compared with more classic NRTI-containing regimens in randomized and controlled clinical trials.

Choosing an initial antiretroviral regimen is one of the most important decisions faced by clinicians managing HIV disease. Numerous antiretroviral combination regimens have shown potency sufficient to achieve viral suppression in most treated patients.1,2 Other criteria to take into account are durability of antiviral suppression, tolerability, risk of long-term toxicity, and patient convenience.3,4 Based on these considerations and on results of comparative trials, most international treatment guidelines recommend 2 first-line regimens consisting of a backbone of 2 nucleoside reverse transcriptase inhibitors (NRTIs), with 1 of them being lamivudine or emtricitabine, and lopinavir/ritonavir or efavirenz.5,6

Lopinavir/ritonavir is considered the preferred protease inhibitor (PI) because of its high antiviral potency and durability as well as acceptable patient tolerance, and efavirenz is the preferred nonnucleoside reverse transcriptase inhibitor (NNRTI).5,7 Although the advantages associated with all classes of antiviral drugs are numerous, several disadvantages do exist. PIs are associated with an increased risk of lipodystrophy, hyperlipidemia, and insulin resistance.5 The principal limitation of NNRTIs is the high risk of cross-class resistance that occurs in the setting of suboptimal adherence or potency. Although numerous published clinical trials involving 1 or more NRTIs clearly demonstrate the utility of NRTI-based treatments, several NRTIs have been associated with mitochondrial toxicity during long-term exposure.8,9 The emergence of resistance mutations to NRTIs in a multiple antiretroviral combination has also been shown to confer variable cross-resistance within the NRTI class.10,11 In the absence of substantial data supporting the potential for alternative approaches, NRTIs have been accepted as an essential component of standard regimens since the beginning of the era of antiretroviral therapy and still are in most recent guidelines.5,6 It could be argued that the third agent, an NNRTI or a PI, mainly drives the potency of modern regimens, however. Indeed, among the 2 “preferred” regimens, most of the potency and durability are likely attributable to efavirenz or lopinavir/ritonavir.12,13 Therefore, an innovative approach would be to construct and evaluate an NRTI-free antiretroviral regimen as part of a broader therapeutic strategy. We designed an open-label proof-of-concept study to assess the immunologic and virologic efficacy and tolerability of an NRTI-free combination of efavirenz and lopinavir/ritonavir in NNRTI-naive HIV-1-infected adults for 48 weeks.

Back to Top | Article Outline


Study Design

The Bitherapy Kaletra-Sustiva (BIKS) trial was a pilot, single-arm, open-label, prospective study designed to evaluate the immunologic and virologic efficacy and safety of lopinavir/ritonavir and efavirenz combination therapy in antiretroviral-naive or, if antiretroviral-experienced, NNRTI-naive HIV-1-infected adults. This multicenter study was conducted at 16 HIV reference centers in France and was approved by the Institutional Review Board of Nantes University Hospital. All patients gave their written informed consent.

Back to Top | Article Outline

To be eligible for enrollment, patients had to meet the following criteria: age ≥18 years, documented HIV-1 seropositivity, CD4 count ≥100 cells/mm3, and plasma HIV-1 RNA level ≥5000 copies/mL. Patients had to be NNRTI naive and, if PI experienced, to have had no more than 1 documented virologic failure on a PI-containing regimen, with less than 5 lopinavir/ritonavir-associated mutations among L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V, and L90M (2001 French algorithm) on screening genotype ( Patients were not eligible if any of the following abnormal laboratory results were documented at screening: hemoglobin <8 g/dL, absolute neutrophil count <750 × 106 cells/L, platelet count <50 × 109 cells/L, aspartate transaminase (AST) or alanine transaminase (ALT) >3 times the upper limit of normal, or creatinine >1.5 times the upper limit of normal.

Back to Top | Article Outline
Treatment Regimen

Lopinavir/ritonavir (Kaletra; Abbott Laboratories, Abbott Park, IL) was prescribed at a dose of 533.3/133.3 mg (4 capsules) twice daily with food. Although standard dosing of lopinavir/ritonavir is 400/100 mg twice daily, a higher dose is recommended to compensate for the decrease in lopinavir plasma exposure when coadministered with efavirenz.14,15 Efavirenz (Sustiva; Bristol-Myers Squibb, New York, NY) was given at a dose of 600 mg (3 capsules) once daily with no food restriction and instructions to take it at bedtime.

The protocol allowed for a dose reduction of lopinavir/ritonavir to 3 capsules (400/100 mg) twice daily in cases of poor gastrointestinal tolerance in the first weeks after treatment initiation and a lopinavir trough plasma concentration level greater than 8 mg/L.

Back to Top | Article Outline
Study Assessment

Patients were evaluated at baseline and at weeks 4, 8, 16, 24, 36, and 48. At each visit, patients underwent a physical examination, laboratory tests (hematology, transaminases, creatinine, fasting glycemia, and lipid levels), CD4 cell count, and plasma viral load measurement. Adherence to treatment was assessed by a self-administered questionnaire in which patients noted the missed doses of study medication during the 4 days before each visit. Nonadherence was defined as an intake less than 80% of prescribed medications. Clinical adverse events were assessed at all study visits. Lipodystrophy was spontaneously reported as an adverse event, and no predefined criteria were used; however, body measurements, including weight, abdominal girth, and waist and hip circumferences, were recorded at each visit. Plasma viral load was measured in real time at the virology laboratory of each participating center by means of a quantitative reverse transcriptase polymerase chain reaction using the standard Amplicor (Roche Molecular Systems, Branchburg, NJ) assay. For samples measuring <400 copies/mL at weeks 24 and 48, a stored plasma sample from the same visit was tested in the central virology laboratory (University Hospital, Nantes, France) by the Ultrasensitive assay (Roche Molecular Systems), with a lower limit of quantification of 50 copies/mL. Virologic failure was defined as any of the 3 following events: (1) 2 consecutive HIV-1 RNA measurements greater than 1000 copies/mL in patients who achieved a viral load less than 400 copies/mL, (2) a decrease in viral load less than 2 log10 within the first 24 weeks, or (3) a viral load remaining greater than 400 copies/mL and confirmed on a subsequent visit from week 24 onward. Genotyping testing was done at baseline and time of failure on plasma samples from patients with virologic failure as well as on all samples from patients with a viral load >400 copies/mL at week 8 and/or week 16. HIV-1 reverse transcriptase and protease mutations associated with drug resistance were defined according to the Agence Nationale de Recherche sur le SIDA (ANRS) AC11 Resistance Algorithm (available at: CD4 cell counts were measured locally by 3-color flow cytometry using commercially available monoclonal antibodies (Becton Dickinson). Trough plasma concentrations of lopinavir and efavirenz were measured simultaneously on stored samples taken at week 4 or at the time of reported digestive intolerance using a validated high-performance liquid chromatography method with a limit of quantification of 0.2 mg/L for both drugs.16,17 For the week 4 trough plasma concentration assessment, samples were only drawn if patients had taken their last dose of lopinavir/ritonavir and efavirenz 12 ± 2 hours before the study visit.

Back to Top | Article Outline
Evaluation Criteria and Statistical Analysis

The primary antiviral end point was the proportion of patients with a plasma viral load less than 400 copies/mL at week 24. Others measures of virologic efficacy included the proportion of patients with a viral load <400 copies/mL at week 48 and <50 copies/mL at weeks 24 and 48, mean decrease of viral load from baseline, and proportion and reasons for virologic failure at weeks 24 and 48. The immunologic efficacy criterion was the mean change in CD4 cell count over the 48-week therapy period. Safety outcomes were evaluated by assessing the incidence of treatment-emergent adverse events and laboratory abnormalities as defined by the AIDS Clinical Trial Group criteria.18 For virologic efficacy, intent-to-treat (ITT) and on-treatment (OT) analyses were performed. For the ITT analysis, missing values and discontinuation of any of the 2 study drugs were handled as treatment failures. Immunologic response was judged by OT analysis. Safety analyses included all patients who received at least 1 dose of study drugs. Data were analyzed by SAS software (version 8.2; SAS Institute, Cary, NC). Statistical evaluation was carried out by the Shapiro-Wilk test, ANOVA, the χ2 test or Fisher exact test, the Student t test or Wilcoxon test, and the Pearson-Spearman correlation (where appropriate), with significant levels placed at P < 0.05.

Back to Top | Article Outline


Patient Characteristics and Disposition

Eighty-six patients were enrolled in the study between May 2001 and April 2002. Patient characteristics and dispositions are shown in Tables 1 and 2. Among the 86 patients, 65 were antiretroviral naive and 21 were pretreated, of whom 12 had only NRTI experience. Among 9 patients with prior PI exposure, genotype testing performed at screening showed no lopinavir-associated mutation in 3 cases, 1 mutation in 4 cases (L63P [n = 3], V82I [n = 1]), 2 mutations in 1 case (L63P + A71T/A), and 3 mutations in 1 case (L10V + L63P + A71T). Of note, among these 9 patients, 5 were still on PI therapy at the time of screening and 4 had interrupted their prior PI therapy for a mean of 15.5 months (range: 8-22 months). Within the 48 weeks of follow-up, treatment discontinuation occurred in 21 (24%) patients. These discontinuations were primarily attributed to emerging adverse events (n = 7) or loss to follow-up (n = 6); only 1 patient discontinued meeting criteria for virologic failure (see Table 2). Adverse event-related discontinuations occurred more frequently during the first 4 weeks of therapy (n = 6, weeks 0-4; n = 1, weeks 4-24; n = 0, weeks 24-48). Among 43 patients who had at least 1 episode of adherence <80% during follow-up, 5 did not complete the initial 24-week period (lost to follow-up or nonadherence) and 2 discontinued the study between weeks 24 and 48 for reasons unrelated to study drugs (pregnancy in the first case and tuberculosis in the second case).

Table 1
Table 1
Image Tools
Table 2
Table 2
Image Tools
Back to Top | Article Outline
Virologic and Immunologic Response

The proportions of patients achieving a plasma viral load <400 copies/mL and <50 copies/mL at weeks 24 and 48 are shown in Table 3. The mean HIV-RNA change from baseline was −2.90 log10 copies/mL at week 24 and −3.00 log10 copies/mL at week 48. The mean (±SD) CD4 count change was 95 (±100) cells/mm3 at week 4, 163 (±149) cells/mm3 at week 24, and 238 (±198) cells/mm3 at week 48. At week 24, 5 patients had a viral load greater than 400 copies/mL, of whom 3 were not considered to be protocol-defined virologic failures: 1 patient had a viral load of 424 copies/mL at week 24 (3.2 log10-copies/mL reduction from baseline) and reached an undetectable viral load at all subsequent visits, and 2 patients had transient virologic rebound to <2000 copies/mL with a viral load <400 copies/mL at immediate subsequent evaluation. The 2 remaining patients were confirmed as experiencing virologic failure: the first had stopped therapy after week 16 for personal reasons, and the second had no reported adherence problems and had a viral load <400 copies/mL at week 16. Genotype testing of a plasma sample from this patient at week 24 demonstrated emergence of the signature resistance mutation for NNRTI (K103N in reverse transcriptase) but no protease mutations. Genotype testing of samples from the remaining 4 patients with a viral load >400 copies/mL only revealed the presence of wild-type virus. At week 48, 2 of the 65 patients who continued the study beyond week 24 had a viral load >400 copies/mL; both patients were nonadherent. Genotype testing showed wild-type virus in the first patient and the K103N mutation in reverse transcriptase in the second patient. At week 48, the ITT analysis of virologic response rate was not different between the 2 subgroups of antiretroviral-naive and pretreated patients (71% and 81%, respectively, of patients with a plasma viral load less than 400 copies/mL; P = 0.359). Patients with a baseline viral load greater than 100,000 copies/mL had a similar rate of virologic success (78%) at week 48 compared with patients with a lower baseline viral load (69%) at week 48 (P = 0.351).

Table 3
Table 3
Image Tools
Back to Top | Article Outline
Safety Assessment

Eight patients (9%) experienced 11 serious clinical adverse events. Four of these events were considered to be drug related by the investigator, including hospitalization for a central nervous system (CNS) disorder in 2 patients and a cutaneous rash in 2 patients. Grade 3 and 4 clinical and laboratory adverse events, regardless of causality, are shown in Table 4. Seven (8%) patients discontinued the study because of drug-related adverse events. This included intolerance to efavirenz with early CNS symptoms in 3 cases and a cutaneous event in 3 cases; 1 patient discontinued the study because of grade 4 dyslipidemia (see Table 2). Fasting lipid levels increased in most patients on treatment at 48 weeks (Fig. 1). After an initial, although not significant, increase between baseline and week 8, the median change in fasting total cholesterol and triglycerides remained stable (0.60 and 1.19 g/L at week 48, respectively; Fig. 2). There were no differences in changes from baseline between antiretroviral-naive and pretreated patients. Mean high-density lipoprotein (HDL) cholesterol significantly increased between baseline and week 48 (0.42 g/L vs. 0.49 g/L, respectively; mean variation = 0.11 g/L; P = 0.019). The percentage of patients with HDL cholesterol >0.4 g/L was 44% at baseline and 80% after 48 weeks of therapy for the antiretroviral-naive group and 41% and 54%, respectively, for antiretroviral-experienced patients. The mean and median total cholesterol/HDL cholesterol ratios did not significantly change between baseline and week 48. A LDL cholesterol level >1.60 g/L was seen in 2% of the antiretroviral-naive patients and 12% of the experienced patients at baseline and in 35% of the antiretroviral-naive patients and 20% of the experienced patients at week 48. At baseline, none of the patients were receiving a lipid-lowering agent. During the course of the study, 3 patients were prescribed a lipid-lowering agent: 1 patient after 8 weeks of therapy for grade 2 hypercholesterolemia, 1 patient after 8 weeks of therapy for grade 3 hypertriglyceridemia, and 1 patient at week 36 for grade 3 hypercholesterolemia. Based on clinical assessment, lipodystrophy was reported in 6 patients, of whom 5 were pretreated: 3 had a prior history of lipodystrophy and experienced subjective self-reported worsening of body changes, whereas 2 developed lipodystrophy after 4 and 16 weeks of therapy, respectively. A mild cheek lipoatrophy occurred after 36 weeks of treatment in 1 treatment-naive patient. No modification in the waist/hip ratio of the total study population was observed at week 24 or 48 compared with baseline.

Figure 1
Figure 1
Image Tools
Figure 2
Figure 2
Image Tools
Table 4
Table 4
Image Tools
Back to Top | Article Outline
Lopinavir and Efavirenz Plasma Concentrations

Trough plasma concentrations of lopinavir and efavirenz were measured in 37 patients who received their last intake of study medication 12 ± 2 hours before the week 4 visit. Mean lopinavir and efavirenz concentrations were within ranges typically observed in patients receiving these agents in combination with NRTIs: 6.22 ± 3.25 mg/L and 2.36 ± 2.58 mg/L, respectively.19-21 No correlation was found between plasma concentrations of lopinavir and efavirenz and initial viral load decrease, CD4 cell response, or increase in fasting lipid levels at week 4. Based on lopinavir plasma concentration results, a decrease in lopinavir/ritonavir dosage to 400/100 mg twice daily was made in 6 cases because of associated digestive intolerance, and an increase in dosage to 667/167 mg twice daily was made in 1 case.

Back to Top | Article Outline
Genotypic Resistance Testing in Slow Responders

Among the 65 treatment-naive patients, the subgroup of slow virologic responders (ie, 19 patients who had a plasma viral load still greater than 400 copies/mL at week 8 or 16 and achieved a viral load less than 400 copies/mL at week 24) was further tested to detect the possible selection and emergence of resistance mutations. Genotypic testing performed on stored samples from baseline and week 8 or 16 revealed the absence of emergence of new resistance mutations in the reverse transcriptase and protease genes.

Back to Top | Article Outline


This study assessed the efficacy and tolerability of an NRTI-sparing regimen of lopinavir/ritonavir and efavirenz in NNRTI-naive patients. Most (76%) of patients were antiretroviral naive, and among the 9 PI-experienced patients, protease resistance mutations at baseline genotypic testing were evidenced in 5, with a major resistance mutation in only 1 case. It should also be noted that among these 9 PI-experienced patients enrolled in the study, 4 had discontinued PI-based therapy before resistance testing at screening, with the possibility that archived resistant variants might thus not have been detected. Still, there was no indication of impaired virologic response in those patients. Overall, patients in this study had moderately advanced HIV infection, with a mean CD4 count just greater than 300 cells/mm3. Approximately three quarters of the patients remained in the study by 48 weeks. Counting all noncompleters as failures, 78% and 73% of patients achieved a plasma viral load less than 400 copies/mL at weeks 24 and 48, respectively; the corresponding numbers for patients achieving a plasma viral load less than 50 copies/mL were 69% at both visits. Of note, plasma viral load was suppressed to less than 400 copies/mL in 93% of the patients who completed 24 weeks on the study medication and to less than 50 copies/mL in 82% of the patients who remained in the study at week 48. These data are within the expected ranges typically seen with most active conventional triple antiretroviral-based combinations.1,22,23 Despite many limitations, NRTIs are still considered an essential part of any recommended first-line antiretroviral combination.5,6 This is most likely attributable to limited experience and data with NRTI-sparing regimens for first-line therapy. Indeed, initial results of other NRTI-sparing regimens, such as those using a combination of indinavir and efavirenz, demonstrated the inferiority of this dual combination when compared with lamivudine/zidovudine (fixed-dose combination; Combivir) with efavirenz but not when compared with lamivudine/zidovudine (fixed-dose combination) with indinavir.12 This outcome may be related to the use of a regimen with a high pill burden, (ie, 200-mg pills of unboosted indinavir taken 3 times daily) as well as to the negative pharmacokinetic interaction between efavirenz and indinavir.24 In a study of 57 multiple NRTI- and PI-experienced patients who were NNRTI naive, the combination of lopinavir/ritonavir-efavirenz plus NRTIs was able to obtain a viral load less than 400 copies/mL at week 72 in 67% of the patients with the ITT analysis and in 88% with the OT analysis.25 Of note, based on prestudy extensive NRTI exposure, it can be assumed that the backbone NRTIs in the latter study did not make a major contribution to the observed efficacy. Dual-PI combination therapy using ritonavir and saquinavir has been associated with a good immunovirologic response; however, this combination has demonstrated disadvantages associated with safety and pill burden issues.26 The combination of lopinavir/ritonavir and efavirenz was shown to have a good rate of immunologic and virologic efficacy in our pilot study. This is the first clinical trial demonstrating efficacy of a lopinavir/ritonavir plus efavirenz NRTI-free regimen. Within 48 weeks of follow-up, we observed only 1 true documented virologic failure on therapy, and failure attributable to nonadherence was also infrequent. We chose to optimize the lopinavir/ritonavir dosage by increasing the daily dose by one third (ie, 4 pills taken twice daily) to counterbalance the negative pharmacokinetic interaction induced by efavirenz.14,15,25,27,28 Previously reported pharmacokinetic studies have demonstrated that dose adjustment of lopinavir/ritonavir provides lopinavir levels in the presence of efavirenz similar to those obtained with a standard dose of lopinavir/ritonavir and NRTIs.20,21 Regarding safety, only 1 patient stopped the study medication because of a lopinavir/ritonavir-related side effect (ie, grade 4 hypertriglyceridemia). Most discontinuations occurred early, during the first month of treatment, and the main reasons for discontinuation were efavirenz-related adverse events. Because of the pilot nature of the study and to assess the chosen regimen better, we did not allow an efavirenz-nevirapine switch. Such a switch in clinical settings, especially in case of CNS side effects, would allow maintenance of the initial strategy of an NRTI-sparing regimen.29 In addition, the relatively high pill burden of the tested combination (ie, 11 pills taken daily) represents a limitation in the practicability of the regimen explored and could account for some of the discontinuations. Nevertheless, our study has proven the potential of an innovative approach of an NNRTI-PI NRTI-sparing regimen. Because of the documented high potency of lopinavir/ritonavir, the relative contribution of efavirenz to the efficacy of the combination could be questioned. Even if limited and mostly uncontrolled data on lopinavir/ritonavir as single-agent therapy have shown the potential of this monotherapy, failures have been reported, with the need for intensification of lopinavir/ritonavir with NRTIs.30,31 Few cases of the emergence of protease gene resistance mutations have been reported in patients failing therapy with lopinavir-ritonavir only.32,33 We therefore believe that until controlled comparative clinical studies have proven that a boosted PI as a single agent is as effective as combination therapy, the concept of combining antiretrovirals should remain the rule for any given antiretroviral regimen. In patients receiving a PI-containing antiretroviral regimen, the prevalence of hyperlipidemia ranges from 28% to 80%, including hypertriglyceridemia in most cases (40%-80%) as well as hypercholesterolemia (10%-50%).34-36 Hypertriglyceridemia seems to be more frequent in patients receiving ritonavir-containing therapy.36-38 The NNRTIs cause alterations in the lipid profile, although generally to a lesser degree than what is observed with some PIs.39-42 As expected, in our study, the combination of lopinavir/ritonavir and efavirenz led to a rapid, although not significant, increase of fasting triglycerides and total cholesterol, with the maximum increase being achieved by week 4 or 8, followed by stabilization up to week 48. These results suggest a combined effect of both drugs in increased lipids. Interestingly, the HDL cholesterol level significantly improved over 48 weeks, whereas the total cholesterol/HDL cholesterol ratio did not change over time.41

Another important finding of our study is the data on emergence of resistance. NNRTI resistance was only documented in 2 patients by week 48 and in none of the slow responders, whereas none of the patients with a detectable viral load during follow-up had protease-resistant viruses selected. These results confirm previous data with lopinavir/ritonavir-based triple regimens in antiretroviral-naive patients.43

In conclusion, this pilot study has proven that an NRTI-sparing regimen combining a potent boosted PI, lopinavir/ritonavir, and a potent NNRTI, efavirenz, is associated with a high rate of virologic success for up to 48 weeks as well as a sustained immunologic response. Most discontinuations were not related to adverse event emergence or virologic failure and could have been related to the pill burden of the formulations used in this study. The availability of a more convenient formulation of efavirenz should lessen the risk of dropouts unrelated to tolerability problems. In addition, the relative lack of drug resistance or virologic failure among subjects who remained on the medication holds promise for this regimen. Larger randomized and controlled trials are needed to assess the immunologic and virologic response further, to evaluate the safety of a PI-NNRTI combination compared with standard NRTI-inclusive regimens, and to determine the best components, in terms of efficacy and safety as well as convenience, within the NNRTI and the boosted PI drug classes.

Back to Top | Article Outline


The authors thank all patients, investigators, virologists, and pharmacists at the clinical sites. We are indebted to Scott Brun, Isabelle Cohen Codar, Kevin Garren, and Philippe N' Govan from Abbott and to Dan Chiche, Mike Giordano, and Thu Huyen Nguyen from Bristol-Myers Squibb, France, for valuable discussions during study design and the preparation of the manuscript. The authors thank Anne-Sophie Poirier and Nathalie Raimbault and CHU de Nantes for technical assistance.

Back to Top | Article Outline


1. Bartlett JA, De Masi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001;15:1369-1377.

2. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-1880.

3. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis. 2003;37:714-722.

4. Trotta MP, Ammassari A, Melzi S, et al. Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S128-S131.

5. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. October 29, 2004. Available at: http// Accessed February 5, 2005.

6. Yéni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection. 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.

7. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.

8. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56.

9. Brinkman K, Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.

10. Iversen AK, Shafer RW, Wehrly K, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol. 1996;70:1086-1090.

11. Wainberg MA, Turner D. Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr. 2004;37(Suppl):S36-S43.

12. Staszewski S, Morales-Ramirez J, Tashima KT, et al, for the Study 006 Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med. 1999;341:1865-1873.

13. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;18:775-779.

14. Hsu A, Isaacson J, Brun S, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2003;47:350-359.

15. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interaction between lopinavir/ritonavir (ABT-378/r) and other non-HIV drugs. AIDS. 2000;14 (Suppl 4):S100.

16. Tribut O, Arvieux C, Michelet C, et al. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase. Ther Drug Monit. 2002;24:554-562.

17. Dailly E, Thomas L, Kergueris MF, et al. A high performance liquid chromatography assay to determinate the plasma levels of 5 HIV-protease inhibitors (amprenavir, indinavir, nelfinavir, ritonavir and saquinavir) and the non-nucleoside reverse transcriptase inhibitor (nevirapine) after liquid-liquid extraction. J Chromatogr B Biomed Appl. 2001;758:129-135.

18. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institute of Health. DAIDS table for grading severity of adult adverse experiences: Adult AIDS Clinical Trials Group. Available at: Accessed June 15, 2004.

19. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS. 2001;15:71-75.

20. Breilh D, Pellegrin I, Rouzès A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study). AIDS. 2004;18:1305-1310.

21. Murphy R, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 2001;15(Suppl):F1-F9.

22. Saag M, Cahn P, Raffi F, et al, for the FTC-301A Study Team. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients. A randomized trial. JAMA. 2004;292:180-190.

23. Gallant JE, Staszewski S, Pozniak AL, et al, for the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.

24. Sustiva [package insert]. Wilmington, DE: DuPont Pharmaceuticals; 2002.

25. Danner S, Brun S, Sylte J, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72 week safety/efficacy evaluation and phenotypic/genotypic breakpoints in multiple PI experienced patients [abstract I 1925]. Presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001; Chicago.

26. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999;13:213-224.

27. Solas C, Poizot-Martin I, Drogoul MP, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol. 2003;57:436-440.

28. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63:769-802.

29. Gulick RM, Ribaudo HJ, Shikuma CM, et al, for the AIDS Clinical Trials Group Study 15095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.

30. Gathe JC, Washington MY, Mayberry C, et al. IMANI-1 TC3WP single drug HAART-proof of concept study. Pilot study of the safety and efficacy of Kaletra (LPV/r) as single drug HAART in HIV + ARV-naive patients-interim analysis of subjects completing final 48 week data [abstract MoOrB1057]. Presented at: 15th International AIDS Conference; 2004; Bangkok.

31. Arribas JR, Pulido F, Lorenzo A, et al. Simplification to lopinavir/r single-drug HAART: 24 weeks results of a randomized, controlled, open label, pilot clinical trial (OK Study) [abstract TuPeB4486]. Presented at: 15th International AIDS Conference; 2004; Bangkok.

32. Conradie F, Sanne I, Venter W, et al. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS. 2004;18:1084-1085.

33. Friend J, Parkin N, Liegler T, et al. Isolated lopinavir resistance after virological rebound of a lopinavir/ritonavir-based regimen. AIDS. 2004;18:1965-1966.

34. Saves M, Raffi F, Capeau J, et al, for the APROCO Study Group. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-1405.

35. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: physiopathology, prevalence, risk factors and treatment. Scand J Infect Dis. 2000;32:111-123.

36. Martinez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis. 2004;38:1017-1023.

37. Calza L, Manfredi R, Farneti B, et al. Incidence of hyperlipidemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2003;22:54-59.

38. Calza L, Manfredi R, Chiodo F. Hyperlipidaemia in patients receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. Int J Antimicrob Agents. 2003;22:89-99.

39. Dubé MP, Stein JS, Aberg JA, et al, for the Adult AIDS Clinical Trials Group Cardiovascular Subcommittee. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.

40. Friis-Møller N, Weber R, Reiss P, et al, for the DAD Study Group. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.

41. Van Leth F, Phanuphak P, Gazzard B, et al. Lipid changes in a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine (2NN study) [abstract 752]. Presented at: 10th Conference on Retroviruses and Opportunistic Infection; 2003; Boston.

42. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257-275.

43. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004;189:51-60.

Back to Top | Article Outline

The BIKS Study Group includes the following individuals:

Data monitoring and analysis: Catherine Rabreau and Fovea (Nicolas Le Gall, Isabelle Pascal, Franck Sevenier).

Clinical centers and principal investigators: Hôtel-Dieu, Nantes (François Raffi); Hôpital Avicenne, Bobigny (Michelle Bentata and Odile Launay); Hôpital Bretonneau, Tours (Jean Marc Besnier); Hôtel-Dieu, Clermont-Ferrand (Christine Jacomet); Hôpital Bicêtre, Paris (Jean François Delfraissy); Hôpital de l'Archet, Nice (Pierre Dellamonica); Hôpital Nord, Marseille (Jacques Moreau); Hôpital Pitié-Salpétrière, Paris (Christine Katlama and Manuela Bonmarchand); Hôpital Chalucet, Toulon (Alain Lafeuillade); Hôpital Pontchaillou, Rennes (Christian Michelet); Hôpital Saint Louis, Paris (Jean Michel Molina); Hôpital Muller, Mulhouse (Geneviève Beck-Wirth), Hôpital Saint Marguerite, Marseille (Isabelle Poizot-Martin); and Hôpital Les Oudairies, La Roche sur Yon (Philippe Perré).


lopinavir/ritonavir; efavirenz; nucleoside reverse transcriptase inhibitor-sparing regimen; nonnucleoside reverse transcriptase inhibitor; boosted protease inhibitor

© 2005 Lippincott Williams & Wilkins, Inc.


Article Tools



Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.